Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
Anne M. Hause, Paige Marquez, Bicheng Zhang, John R. Su, Tanya R. Myers, Julianne Gee, S. Panchanathan, Deborah Thompson, Tom T. Shimabukuro, David K. Shay
Abstract
This report describes similar early safety findings from the Vaccine Adverse Event Reporting System for bivalent booster vaccination in children aged 5â11 years as the monovalent booster vaccination.
Topics & Concepts
Bivalent (engine)MedicineBooster (rocketry)Booster doseAdverse effectVaccinationAuthorizationPediatricsTiterVirologyInternal medicineVirusOrganic chemistryChemistryAstronomyComputer scienceMetalComputer securityPhysicsPharmaceutical studies and practicesSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy